



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: THE LIPOSOME COMPANY, INCApplication No./Patent No.: 09/429,694 Filed/Issue Date: 10/27/99Entitled: Liposome Ceramide-Related Compounds with the Therapeutic Use ThereofThe Liposome Company, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 7579, Frame 0405, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

11/20/00

Date

Rosanne Goodman

Typed or printed name

Rosanne Goodman

Signature

Assistant Secretary

Title

RECEIVED

NOV 27 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of : Yong Wei et al.
 Serial No. : 09/429,694
 Filed : October 27, 1999
 For : LIPOSOMAL CERAMIDE-RELATED LIPOSOMES AND THE THERAPEUTIC USE THEREOF

Examiner: G. Kishore

Art Unit: 1615

TECH CENTER 1600

Atty. Dkt. No.: TLC-144C-RIS

Honorable Commissioner of
 Patents and Trademarks
 Washington, D.C. 20231

Pat
 11-30-00

"Express Mail" mailing label number EF209421200US

Date of Deposit November 20, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on November 20, 2000.

Rosanne Goodman

(Typed or printed name of person mailing paper or fee)

Rosanne Goodman
 (Signature of person mailing paper or fee)

Response

In response to the Office Action dated October 27, 2000, we submit the following claims 1, 16 and 27, re-formatted to comply with re-issue application rules:

1. (amended) A liposome having a bilayer comprising a lipid component which comprises a compound having the formula $R^1-Y^1-CHZ^1-CH(NY^2Y^3)-CH_2-Z^2$, wherein:
- R^1 is a straight-chained alkyl, alkenyl or alkynyl group having from 5 to 19 carbon atoms in the aliphatic chain;
- Y^1 is $-CH=CH-$, $-C\equiv C-$ or $-CH(OH)CH(OH)-$;
- each of Z^1 and Z^2 is independently OH or a conversion-inhibiting group;
- Y^2 is a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons;
- Y^3 is H or a group having the formula $-C(O)R^2$ or $-S(O)_2R^2$;